Banco Bilbao Vizcaya Argentaria S.A. Purchases 5,941 Shares of CVS Health Corporation $CVS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. lifted its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 2.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 306,260 shares of the pharmacy operator's stock after purchasing an additional 5,941 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in CVS Health were worth $20,740,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Ossiam raised its stake in shares of CVS Health by 45.8% in the 4th quarter. Ossiam now owns 33,586 shares of the pharmacy operator's stock valued at $1,508,000 after acquiring an additional 10,553 shares in the last quarter. MetLife Investment Management LLC raised its position in shares of CVS Health by 1.8% in the fourth quarter. MetLife Investment Management LLC now owns 333,134 shares of the pharmacy operator's stock valued at $14,954,000 after purchasing an additional 5,964 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of CVS Health by 40.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 70,218 shares of the pharmacy operator's stock worth $3,152,000 after buying an additional 20,107 shares during the last quarter. State of Tennessee Department of Treasury boosted its holdings in shares of CVS Health by 4.7% during the 4th quarter. State of Tennessee Department of Treasury now owns 477,251 shares of the pharmacy operator's stock worth $21,424,000 after buying an additional 21,251 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in CVS Health by 14.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,366,403 shares of the pharmacy operator's stock valued at $600,019,000 after buying an additional 1,660,321 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of NYSE:CVS traded up $0.5810 during trading on Thursday, hitting $71.4010. 7,069,976 shares of the stock were exchanged, compared to its average volume of 9,017,101. The company has a market capitalization of $90.56 billion, a price-to-earnings ratio of 19.94, a price-to-earnings-growth ratio of 0.78 and a beta of 0.58. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $72.51. The company's fifty day simple moving average is $65.43 and its 200-day simple moving average is $65.01.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.CVS Health's quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd were paid a dividend of $0.665 per share. The ex-dividend date was Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 3.7%. CVS Health's dividend payout ratio (DPR) is currently 74.30%.

Insiders Place Their Bets

In related news, Director Guy P. Sansone acquired 1,570 shares of the stock in a transaction dated Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the purchase, the director owned 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.22% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CVS shares. UBS Group upgraded shares of CVS Health from a "neutral" rating to a "buy" rating and upped their price target for the company from $67.00 to $79.00 in a report on Monday. Truist Financial increased their target price on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Royal Bank Of Canada raised their target price on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Jefferies Financial Group upped their price target on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 30th. Finally, Baird R W raised shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, CVS Health presently has an average rating of "Buy" and a consensus target price of $76.67.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.